MOMO'S BREAKOUT BOARD

[powerbattles]

$CTOR $1.24 ✨💎✨💎✨💎✨💎✨💎Next monster is one of the lowest floaters in the market. With Lymphir's FDA approval and another drug awaiting its NDA submission. Market Cap Market Cap 2,708,536 is incredibly low. This stock is set for a massive move. It's the best bargain, and super undervalued. No offering, no dilute. Outstanding Shares 2,355,249. The chart looks poised for the run. This will fly soon! It’s a matter of time Bullish.

Lymphir is the only CTCL therapy that targets the interleukin-2 (IL-2) receptor found on malignant T-cells and Tregs. This is the first indication for Lymphir and Citius Pharma’s first FDA-approved product.

Mino-Lok (For Cancer and Infection Prevention)
Successful Phase 3 Clinical Trial of Mino-Lok®. Mino-Lok® is on a pathway to a New Drug Application (NDA) submission which includes all the clinical trial data, manufacturing details, labeling information, and proposed use for the drug.

Phase 2 clinical trials. 1. CanStem 303C (Stem Cell Therapy for Cancer)
CanStem 303C is one of Citius Oncology's lead candidates. It's an investigational cell therapy aimed at treating cancer relapse and recurrence.